Skip to main content
Erschienen in: Current Gastroenterology Reports 1/2011

01.02.2011

Prevention and Treatment of Postoperative Crohn’s Disease Recurrence: An Update for a New Decade

Erschienen in: Current Gastroenterology Reports | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Poorly controlled Crohn’s disease (CD) often requires surgery for such complications as strictures, fistulas, and abscesses. The goal of postoperative treatment is to suppress or prevent inflammation and maintain mucosal healing. Probiotics, antibiotics, 5-aminosalicylates, immunomodulators, and antibodies to tumor necrosis factor are all used to prevent postoperative recurrence. In this article, recent studies are reviewed. Azathioprine/6-mercaptopurine are moderately effective at preventing and treating postoperative CD, whereas infliximab/adalimumab are highly effective and probiotics and 5-aminosalicylates minimally effective. We base the choice of postoperative medical therapy on the patient’s risk profile for postoperative recurrence. Whatever postoperative therapy is used, the mucosa should be assessed within 12 months to determine if the approach is effective. If active inflammation is found, then treatment should be intensified. By treating CD aggressively after a first surgery, future surgeries can be delayed or averted.
Literatur
1.
Zurück zum Zitat Loftus EV, Schoenfeld P, Sandborn WJ: The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002, 16:51–60.CrossRefPubMed Loftus EV, Schoenfeld P, Sandborn WJ: The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002, 16:51–60.CrossRefPubMed
2.
Zurück zum Zitat Olaison G, Sjodahl R, Tagesson C: Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990, 31:325–328.CrossRefPubMed Olaison G, Sjodahl R, Tagesson C: Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990, 31:325–328.CrossRefPubMed
3.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, et al.: Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984, 25:665–672.CrossRefPubMed Rutgeerts P, Geboes K, Vantrappen G, et al.: Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984, 25:665–672.CrossRefPubMed
4.
Zurück zum Zitat Olaison G, Smedh K, Sjodahl R: Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992, 33:331–335.CrossRefPubMed Olaison G, Smedh K, Sjodahl R: Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992, 33:331–335.CrossRefPubMed
5.
Zurück zum Zitat Rutgeerts P, Diamond RH, Bala M, et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006, 63:433–442.CrossRefPubMed Rutgeerts P, Diamond RH, Bala M, et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006, 63:433–442.CrossRefPubMed
6.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99:956–963.PubMed Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99:956–963.PubMed
7.
Zurück zum Zitat • Doherty G, Bennett G, Patil S, et al.: Interventions for prevention of postoperative recurrence of Crohn’s disease. Cochrane Database Syst Rev 2009(4):CD006873. This article provides a comprehensive review of the medical management of postoperative Crohn’s disease with a high-quality study design. • Doherty G, Bennett G, Patil S, et al.: Interventions for prevention of postoperative recurrence of Crohn’s disease. Cochrane Database Syst Rev 2009(4):CD006873. This article provides a comprehensive review of the medical management of postoperative Crohn’s disease with a high-quality study design.
8.
Zurück zum Zitat Ford AC, Khan KJ, Talley NJ, Moayyedi P: 5-Aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2010 (Epub ahead of print). Ford AC, Khan KJ, Talley NJ, Moayyedi P: 5-Aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2010 (Epub ahead of print).
9.
Zurück zum Zitat Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.CrossRefPubMed Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.CrossRefPubMed
10.
Zurück zum Zitat Lichtenstein GR, Yan S, Bala M, et al.: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005, 128:862–869.CrossRefPubMed Lichtenstein GR, Yan S, Bala M, et al.: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005, 128:862–869.CrossRefPubMed
11.
Zurück zum Zitat Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723–729.CrossRefPubMed Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723–729.CrossRefPubMed
12.
Zurück zum Zitat Rutgeerts P, Hiele M, Geboes K, et al.: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995, 108:1617–1621.CrossRefPubMed Rutgeerts P, Hiele M, Geboes K, et al.: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995, 108:1617–1621.CrossRefPubMed
13.
Zurück zum Zitat Rutgeerts P, Van Assche G, Vermeire S, et al.: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005, 128:856–861.CrossRefPubMed Rutgeerts P, Van Assche G, Vermeire S, et al.: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005, 128:856–861.CrossRefPubMed
14.
Zurück zum Zitat Chermesh I, Tamir A, Reshef R, et al.: Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig Dis Sci 2007, 52:385–389.CrossRefPubMed Chermesh I, Tamir A, Reshef R, et al.: Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig Dis Sci 2007, 52:385–389.CrossRefPubMed
15.
Zurück zum Zitat Van Gossum A, Dewit O, Lewis E, et al.: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-caecal resection. Inflamm Bowel Dis 2007, 13:135–142.CrossRefPubMed Van Gossum A, Dewit O, Lewis E, et al.: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-caecal resection. Inflamm Bowel Dis 2007, 13:135–142.CrossRefPubMed
16.
Zurück zum Zitat Marteau P, Lemann M, Seksik P, et al.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842–847.CrossRefPubMed Marteau P, Lemann M, Seksik P, et al.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842–847.CrossRefPubMed
17.
Zurück zum Zitat Madsen K, Backer JL, Leddin D, et al.: A randomized controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn’s disease. Gastroenterology 2010, 138(Suppl 1):A361. Madsen K, Backer JL, Leddin D, et al.: A randomized controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn’s disease. Gastroenterology 2010, 138(Suppl 1):A361.
18.
Zurück zum Zitat Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995, 37:674–678.CrossRefPubMed Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995, 37:674–678.CrossRefPubMed
19.
Zurück zum Zitat Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004, 127:730–740.CrossRefPubMed Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004, 127:730–740.CrossRefPubMed
20.
Zurück zum Zitat Nos P, Hinojosa J, Aguilera V et al.: Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterol Hepatol 2000, 23:374–378.PubMed Nos P, Hinojosa J, Aguilera V et al.: Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterol Hepatol 2000, 23:374–378.PubMed
21.
Zurück zum Zitat •• D’Haens GR, Vermeire S, Van Assche G, et al.: Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 2008, 135:1123–1129. This important study showed the superior efficacy of azathioprine and antibiotics to antibiotics alone for the prevention of postoperative Crohn’s recurrence, using endoscopic recurrence as the primary endpoint.CrossRefPubMed •• D’Haens GR, Vermeire S, Van Assche G, et al.: Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 2008, 135:1123–1129. This important study showed the superior efficacy of azathioprine and antibiotics to antibiotics alone for the prevention of postoperative Crohn’s recurrence, using endoscopic recurrence as the primary endpoint.CrossRefPubMed
22.
Zurück zum Zitat Reinisch W, Angelberger S, Petritsch W, et al.: Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752–759.CrossRefPubMed Reinisch W, Angelberger S, Petritsch W, et al.: Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752–759.CrossRefPubMed
23.
Zurück zum Zitat Sorrentino D, Terrosu G, Avellini C, Maiero S: Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007, 167:1804–1807.CrossRefPubMed Sorrentino D, Terrosu G, Avellini C, Maiero S: Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007, 167:1804–1807.CrossRefPubMed
24.
Zurück zum Zitat •• Regueiro M, Schraut W, Baidoo L, et al.: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009, 136:441–450. This article describes the first randomized controlled trial to show the dramatic benefit of infliximab compared to other postoperative therapies as a means of preventing postoperative endoscopic recurrence of CD.CrossRefPubMed •• Regueiro M, Schraut W, Baidoo L, et al.: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009, 136:441–450. This article describes the first randomized controlled trial to show the dramatic benefit of infliximab compared to other postoperative therapies as a means of preventing postoperative endoscopic recurrence of CD.CrossRefPubMed
25.
Zurück zum Zitat Regueiro M, Kip K, Schraut W, et al.: Long-term follow-up of patients enrolled in the randomized controlled trial of infliximab for prevention of postoperative Crohn’s disease. Am J Gastroenterol 2009, 104:S459. Regueiro M, Kip K, Schraut W, et al.: Long-term follow-up of patients enrolled in the randomized controlled trial of infliximab for prevention of postoperative Crohn’s disease. Am J Gastroenterol 2009, 104:S459.
26.
Zurück zum Zitat • Yamamoto T, Umegae S, Matsumoto K: Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm Bowel Dis 2009, 15:1460–1466. This article describes a unique head-to-head treatment study which, although the enrollment was small, suggested that infliximab induced mucosal healing better than azathioprine, which in turn was more effective than mesalamine. Furthermore, the investigators found that mucosal healing is possible with aggressive therapy, even after postoperative recurrence.CrossRefPubMed • Yamamoto T, Umegae S, Matsumoto K: Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm Bowel Dis 2009, 15:1460–1466. This article describes a unique head-to-head treatment study which, although the enrollment was small, suggested that infliximab induced mucosal healing better than azathioprine, which in turn was more effective than mesalamine. Furthermore, the investigators found that mucosal healing is possible with aggressive therapy, even after postoperative recurrence.CrossRefPubMed
27.
Zurück zum Zitat • Fernandez-Blanco I, Monturiol J, Martinez B et al.: Adalimumab in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterology 2010, 138(Suppl 1):S692. Because this study is not placebo-controlled, the data should be considered preliminary. However, it is the first to evaluate postoperative adalimumab and, as expected, found that adalimumab has similar efficacy to infliximab for preventing postoperative Crohn’s recurrence. • Fernandez-Blanco I, Monturiol J, Martinez B et al.: Adalimumab in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterology 2010, 138(Suppl 1):S692. Because this study is not placebo-controlled, the data should be considered preliminary. However, it is the first to evaluate postoperative adalimumab and, as expected, found that adalimumab has similar efficacy to infliximab for preventing postoperative Crohn’s recurrence.
28.
Zurück zum Zitat Yamamoto T: Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005, 11:3971–3979.PubMed Yamamoto T: Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005, 11:3971–3979.PubMed
29.
Zurück zum Zitat Cosnes J, Carbonnel F, Beaugerie L, et al.: Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 1996, 110:424–431.CrossRefPubMed Cosnes J, Carbonnel F, Beaugerie L, et al.: Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 1996, 110:424–431.CrossRefPubMed
30.
Zurück zum Zitat Avidan B, Sakhnini E, Lahat A, et al.: Risk factors regarding the need for a second operation in patients with Crohn’s disease. Digestion 2005, 72:248–253.CrossRefPubMed Avidan B, Sakhnini E, Lahat A, et al.: Risk factors regarding the need for a second operation in patients with Crohn’s disease. Digestion 2005, 72:248–253.CrossRefPubMed
31.
Zurück zum Zitat Greenstein AJ, Lachman P, Sachar DB, et al.: Perforating and nonperforating indications for repeated operations in Crohn’s disease: evidence for two clinical forms. Gut 1988, 29:588–592.CrossRefPubMed Greenstein AJ, Lachman P, Sachar DB, et al.: Perforating and nonperforating indications for repeated operations in Crohn’s disease: evidence for two clinical forms. Gut 1988, 29:588–592.CrossRefPubMed
32.
Zurück zum Zitat Lautenbach E, Berlin JA, Lichtenstein GR: Risk factors for early postoperative recurrence of Crohn’s disease. Gastroenterology 1998, 115:259–267.CrossRefPubMed Lautenbach E, Berlin JA, Lichtenstein GR: Risk factors for early postoperative recurrence of Crohn’s disease. Gastroenterology 1998, 115:259–267.CrossRefPubMed
33.
Zurück zum Zitat Regueiro M: Management and prevention of postoperative Crohn’s disease. Inflamm Bowel Dis 2009, 15:1583–1590.CrossRefPubMed Regueiro M: Management and prevention of postoperative Crohn’s disease. Inflamm Bowel Dis 2009, 15:1583–1590.CrossRefPubMed
Metadaten
Titel
Prevention and Treatment of Postoperative Crohn’s Disease Recurrence: An Update for a New Decade
Publikationsdatum
01.02.2011
Erschienen in
Current Gastroenterology Reports / Ausgabe 1/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0152-x

Weitere Artikel der Ausgabe 1/2011

Current Gastroenterology Reports 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.